Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis.
Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, Winterberg D, Mary C, Corallo F, Taurelle J, Narbeburu E, Neyton SL, Déramé M, Pengam S, Vogiatzi F, Bornhauser B, Bourquin JP, Raffel S, Dovhan V, Schüler T, Escherich G, den Boer ML, Boer JM, Wessels W, Peipp M, Alten J, Antić Ž, Bergmann AK, Schrappe M, Cario G, Brüggemann M, Poirier N, Schewe DM. Lenk L, et al. Among authors: mary c. Blood. 2024 Mar 22:blood.2023021088. doi: 10.1182/blood.2023021088. Online ahead of print. Blood. 2024. PMID: 38518105 Free article.
ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression.
Lavy M, Gauttier V, Dumont A, Chocteau F, Deshayes S, Fresquet J, Dehame V, Girault I, Trilleaud C, Neyton S, Mary C, Juin P, Poirier N, Barillé-Nion S, Blanquart C. Lavy M, et al. Among authors: mary c. Front Immunol. 2023 Jul 19;14:1196731. doi: 10.3389/fimmu.2023.1196731. eCollection 2023. Front Immunol. 2023. PMID: 37539056 Free PMC article.
First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7Rα.
Poirier N, Baccelli I, Belarif L, Abès R, Teppaz G, Mary C, Poli S, Fromond C, Girault I, Pengam S, Soma E, De Sa F, Conduzorgues JP, Braudeau C, Josien R, Volckaert B, Costantini D, Corallo F. Poirier N, et al. Among authors: mary c. J Immunol. 2023 Mar 15;210(6):753-763. doi: 10.4049/jimmunol.2200635. J Immunol. 2023. PMID: 36734626 Clinical Trial.
CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy.
Drouin M, Saenz J, Gauttier V, Evrard B, Teppaz G, Pengam S, Mary C, Desselle A, Thepenier V, Wilhelm E, Merieau E, Ligeron C, Girault I, Lopez MD, Fourgeux C, Sinha D, Baccelli I, Moreau A, Louvet C, Josien R, Poschmann J, Poirier N, Chiffoleau E. Drouin M, et al. Among authors: mary c. Sci Adv. 2022 Nov 16;8(46):eabo7621. doi: 10.1126/sciadv.abo7621. Epub 2022 Nov 18. Sci Adv. 2022. PMID: 36399563 Free PMC article.
Overcoming COVID-19 disruptions: Innovations in product provision in a multi-national clinical trial among cisgender men, transgender men and transgender women in five countries.
Cindy J, Sherri J, Tarana B, Lynn M, Mary C, Sibuiswe G, Veruree M, Karina P, Jillian Z, Yuqing J, Jose B. Cindy J, et al. Among authors: mary c. Contemp Clin Trials Commun. 2022 Aug;28:100930. doi: 10.1016/j.conctc.2022.100930. Epub 2022 Jun 6. Contemp Clin Trials Commun. 2022. PMID: 35693378 Free PMC article.
Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth.
De Marco M, Gauttier V, Pengam S, Mary C, Ranieri B, Basile A, Festa M, Falco A, Reppucci F, Cammarota AL, Acernese F, De Laurenzi V, Sala G, Brongo S, Miyasaka M, Shalapour S, Vanhove B, Poirier N, Iaccarino R, Karin M, Turco MC, Rosati A, Marzullo L. De Marco M, et al. Among authors: mary c. Cell Death Discov. 2022 Mar 3;8(1):94. doi: 10.1038/s41420-022-00817-9. Cell Death Discov. 2022. PMID: 35241649 Free PMC article.
153 results